Market Capitalization (Millions $) |
1,761 |
Shares
Outstanding (Millions) |
570 |
Employees |
46 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-34 |
Cash Flow (TTM) (Millions $) |
94 |
Capital Exp. (TTM) (Millions $) |
0 |
Mereo Biopharma Group Plc
Mereo Biopharma Group Plc is a UK-based clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics for rare and specialty diseases. The company is dedicated to developing therapies that have the potential to transform the lives of patients affected by diseases that currently have limited or no treatment options. Mereo Biopharma aims at commercializing these therapies through partnerships or in-house efforts.
Mereo Biopharma has a diversified pipeline of clinical-stage product candidates that range from rare metabolic disorders to oncology. The company's lead program is setrusumab, which is in Phase 3 development for osteogenesis imperfecta, a rare genetic bone disorder. The company also has an active clinical program in the treatment of Alport syndrome, a rare genetic kidney disease. Additionally, the company is developing navicixizumab, which is in Phase 1b/2a development for the treatment of cancers with high unmet medical needs, such as pancreatic and ovarian cancers.
Mereo Biopharma has a strong track record of partnering with leading pharmaceutical companies to advance its pipeline programs to commercialization. The company has formed collaborations with Novartis, Oncomed, and Ultragenyx Pharmaceutical, among others.
Mereo Biopharma was founded in 2015 and is headquartered in London, UK, with offices in the US and Europe. The company has a dedicated team of experienced professionals who have extensive expertise in drug development and commercialization. Mereo Biopharma has a market capitalization of approximately e45 million as of June 202
In summary, Mereo Biopharma is a clinical-stage biopharmaceutical company that aims to address unmet medical needs by developing innovative therapies for rare and specialty diseases. The company has a diversified pipeline of clinical-stage product candidates, a successful partnering strategy, and a talented team of professionals dedicated to transforming the lives of patients through cutting-edge therapeutics.
Company Address: One Cavendish Place London 0
Company Phone Number: 333-023-7300 Stock Exchange / Ticker: NASDAQ MREO
MREO is expected to report next financial results on March 27, 2024. |
|
|